ANNX20270115C6
ANNX Jan 15 2027 6.00 Call (ANNX270115C00006000)
option OPRA

our mission is to develop disease-modifying therapeutics for patients suffering from neurological disorders such as huntington's disease and alzheimer's disease by targeting complement-mediated neurodegeneration (cmnd).